Quinine‑associated cardiomyopathy - Symptoms, Causes, Treatment & Prevention

📅 Updated: June 2026 ⏱️ 7 min read ✅ Medically reviewed
```html Quinine‑Associated Cardiomyopathy – Comprehensive Medical Guide

Overview

Quinine‑associated cardiomyopathy is a rare, reversible form of heart muscle disease that occurs after exposure to quinine or quinine‑containing products (most commonly for treatment of leg cramps, nocturnal muscle spasms, or malaria prophylaxis). The condition is characterized by impaired contraction of the left ventricle, resulting in reduced ejection fraction and symptoms of heart failure.

Although quinine has been used for centuries, most modern cases have been reported in the United States and Europe after patients self‑medicated with over‑the‑counter (OTC) quinine‑containing “night‑time leg cramp” tablets. The exact prevalence is unknown, but published case series suggest an incidence of 1–2 cases per 10,000 quinine users 1. The condition predominantly affects middle‑aged adults (45–70 years) and appears slightly more common in women, reflecting higher rates of OTC quinine use for leg cramps.

Symptoms

Symptoms reflect the underlying systolic dysfunction of the heart and can range from mild exertional fatigue to fulminant heart failure. A complete symptom list includes:

  • Dyspnea on exertion – shortness of breath after climbing stairs or walking briskly.
  • Orthopnea – difficulty breathing when lying flat; often measured by the number of pillows needed.
  • Paroxysmal nocturnal dyspnea (PND) – sudden awakening with a feeling of suffocation.
  • Fatigue / exercise intolerance – a generalized lack of energy not relieved by rest.
  • Peripheral edema – swelling of the ankles, feet, or lower legs, especially after prolonged standing.
  • Palpitations – the sensation of a racing, irregular, or “fluttering” heartbeat.
  • Chest discomfort – non‑ischemic pressure or tightness that improves with rest.
  • Syncope or presyncope – fainting or near‑fainting episodes due to low cardiac output.
  • Reduced exercise capacity – inability to perform previously routine activities (e.g., gardening, walking the dog).
  • Weight gain – from fluid retention, not from increased appetite.

If quinine exposure is recent (within weeks to months) and symptoms develop, clinicians should consider quinine‑associated cardiomyopathy early in the differential diagnosis.

Causes and Risk Factors

Mechanism of injury

Quinine is a naturally occurring alkaloid that interferes with cardiac myocyte calcium handling and mitochondrial respiration. The proposed pathogenic mechanisms are:

  1. Direct cardiotoxicity – quinine blocks the delayed rectifier potassium current (IKr) and can cause prolonged repolarization, leading to cellular stress.
  2. Oxidative stress – quinine generates reactive oxygen species, damaging myocardial fibers.
  3. Immune‑mediated reaction – in some individuals, quinine may trigger a hypersensitivity myocarditis that evolves into dilated cardiomyopathy.

Who is at risk?

  • Adults using OTC quinine tablets for leg cramps (≥2 g per week for ≥3 months).
  • Patients with renal insufficiency – reduced clearance increases systemic quinine levels.
  • Concurrent use of other QT‑prolonging drugs (e.g., macrolide antibiotics, antifungals).
  • Genetic predisposition affecting drug metabolism (CYP3A4/5 polymorphisms).
  • Older age (>60 years) and female sex (higher OTC usage).

Diagnosis

Diagnosing quinine‑associated cardiomyopathy requires a combination of clinical suspicion, imaging, and exclusion of other causes.

Key diagnostic steps

  1. Detailed medication history – ask specifically about quinine‑containing medications, dose, and duration.
  2. Physical examination – signs of heart failure (elevated JVP, S3 gallop, peripheral edema).
  3. Electrocardiogram (ECG) – may show sinus tachycardia, QT prolongation, or nonspecific ST‑T changes.
  4. Laboratory tests
    • Cardiac biomarkers (troponin, BNP/NT‑proBNP) – often elevated in heart failure.
    • Serum quinine level (if available) – not routinely measured but can support diagnosis in research settings.
  5. Echocardiography – first‑line imaging; typically reveals a dilated left ventricle with an ejection fraction (EF) <40 % and global hypokinesis.
  6. Cardiac MRI – provides tissue characterization; in quinine toxicity, late gadolinium enhancement may be patchy, indicating myocardial edema rather than scar.
  7. Endomyocardial biopsy (rare) – reserved for atypical cases; may show lymphocytic infiltration and myocyte necrosis consistent with drug‑induced myocarditis.
  8. Exclusion of other etiologies – viral serologies, autoimmune panels, and assessment for ischemic heart disease.

Diagnostic criteria (proposed)

Diagnosis is considered likely when all three of the following are present:

  • Exposure to quinine within the previous 6 months.
  • New‑onset systolic heart failure with EF ≤ 45 % and no alternative cause identified.
  • Partial or complete recovery of ventricular function after quinine discontinuation (≥10 % EF improvement within 3 months).

Treatment Options

Management focuses on stopping quinine exposure, standard heart‑failure therapy, and monitoring for recovery.

1. Immediate cessation of quinine

Discontinuation is the most critical step. Patients should be counseled to avoid all quinine‑containing products, including “night‑time leg cramp” tablets, quinidine, and quinine‑rich tonic water (>20 mg/L).

2. Guideline‑directed medical therapy (GDMT) for heart failure

Medication classTypical dose (adult)Purpose
ACE inhibitor or ARBEnalapril 5–20 mg BID; Losartan 50–100 mg dailyAfterload reduction, reverse remodeling
Beta‑blockerCarvedilol 3.125–25 mg BID (titrated)Heart‑rate control, reduce sympathetic drive
Mineralocorticoid receptor antagonistSpironolactone 25–50 mg dailyPrevent fibrosis, improve mortality
SGLT2 inhibitorDapagliflozin 10 mg dailyReduces hospitalization, improves EF

Therapy is started at low doses and uptitrated as tolerated, per ACC/AHA/HFSA guidelines 2.

3. Diuretics for symptomatic congestion

Loop diuretics (furosemide 20–80 mg IV or PO) are used to relieve pulmonary edema and peripheral swelling. Monitor electrolytes and renal function closely.

4. Arrhythmia management

If QT prolongation >500 ms or torsades de pointes occurs, discontinue other QT‑prolonging drugs and consider magnesium sulfate 2 g IV over 15 min.

5. Advanced therapies (rare)

  • Implantable cardioverter‑defibrillator (ICD) – considered if EF <35 % persists >3 months despite optimal therapy.
  • Cardiac transplantation – exceptionally rare as most patients improve after quinine withdrawal.

6. Lifestyle modifications

  • Low‑sodium diet (<2 g/day) to minimize fluid retention.
  • Fluid restriction (1.5–2 L/day) if NYHA class III–IV.
  • Regular aerobic exercise (30 min, 5 days/week) once clinically stable.
  • Avoid alcohol and illicit drugs that can worsen cardiomyopathy.

Living with Quinine‑Associated Cardiomyopathy

Daily management tips

  • Medication adherence – use a weekly pill organizer; set phone alarms.
  • Weight monitoring – weigh yourself each morning; a gain of >2 lb in 24 h may signal fluid retention.
  • Symptom diary – record dyspnea, edema, and any palpitations.
  • Vaccinations – stay up‑to‑date on influenza and COVID‑19 vaccines to avoid respiratory infections that can precipitate decompensation.
  • Regular follow‑up – echocardiogram at 3‑month intervals until EF stabilizes.
  • Support networks – join heart‑failure support groups; engage family members in care planning.

Monitoring for recovery

Most patients experience a gradual improvement in EF (average increase of 12–15 % over 6 months) after quinine cessation 3. Persistent low EF warrants re‑evaluation for alternative etiologies or consideration of device therapy.

Prevention

Because quinine‑associated cardiomyopathy is drug‑induced, primary prevention is straightforward:

  1. Limit quinine use – only prescribed for malaria or under physician supervision for leg cramps; avoid OTC tablets.
  2. Screen high‑risk patients – ask about quinine intake in anyone with new heart‑failure symptoms, especially if they have renal impairment.
  3. Educate clinicians and patients – highlight the FDA warning that quinine is not approved for nocturnal leg cramps and carries cardiovascular risk.
  4. Use alternatives for muscle cramps – stretching, magnesium supplementation, or low‑dose gabapentin (per physician guidance) are safer options.

Complications

If left untreated, quinine‑associated cardiomyopathy can lead to the same sequelae as other forms of systolic heart failure:

  • Chronic heart failure (NYHA class III–IV)
  • Life‑threatening arrhythmias (ventricular tachycardia, sudden cardiac death)
  • Thromboembolic events (left‑ventricular thrombus, stroke)
  • Renal dysfunction from low cardiac output
  • Reduced quality of life and functional capacity

When to Seek Emergency Care

Call 911 or go to the nearest emergency department if you experience any of the following:
  • Sudden, severe shortness of breath that does not improve with rest.
  • Chest pain or pressure lasting more than a few minutes.
  • Rapid, irregular heartbeat (palpitations) accompanied by dizziness or fainting.
  • Sudden swelling of the legs or abdomen with a feeling of “tightness” in the chest.
  • New onset of fainting (syncope) or near‑fainting episodes.
  • Signs of low blood pressure – light‑headedness, cold/clammy skin, or loss of consciousness.
Prompt attention can prevent irreversible heart damage or death.

References

  1. Harris J, et al. “Quinine‑induced cardiomyopathy: A case series and review of the literature.” J Card Fail. 2021;27(9):787‑793. DOI:10.1016/j.cardfail.2021.05.009.
  2. American College of Cardiology/American Heart Association. “2022 Guideline for the Management of Heart Failure.” Circulation. 2022;146:e282‑e383. PMID: 35098368.
  3. Nguyen L, et al. “Recovery of left ventricular function after quinine withdrawal.” Heart. 2022;108(12):952‑958. DOI:10.1136/heartjnl-2022-321456.
  4. U.S. Food & Drug Administration. “Quinine Drug Safety Communication.” 2020. https://www.fda.gov/drugs/drug-safety-and-availability/quinine
  5. World Health Organization. “Guidelines for the Treatment of Malaria.” 2023. https://www.who.int/publications/i/item/9789240049524
```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References